64x | Enabling next generation medicines
Enabling next generation medicines
A comprehensive platform and product suite for Advanced therapeutics
Designing scalable therapeutic systems
The future of medicine is taking shape, but scaling it remains a challenge. Some of the biggest breakthroughs in next generation therapies are being held back by manufacturing constraints. The science is moving fast, but the infrastructure is still catching up.
Our VectorSelect platform is designed to unlock the scale these therapies need to survive. We combine massively parallelized screens with computational insights to engineer high yield cell lines and production technologies — accelerating the manufacturing of advanced therapies from the inside out.
Gene Therapies
Powered by AAV Apex Suite. High yield AAV production system built for performance across multiple serotypes, payloads, and manufacturing scales.
Cell Therapies
Powered by LV Apex Suite. High yield lentiviral vector production system built to support ex vivo and in vivo CAR-T programs.
Biologics
Powered by our next Apex Suite. High yield biologics production system for antibodies and next generation protein therapeutics.
Change the math for next generation medicines with VectorSelecT and OUR apex suiteS
01
License high performING cell lines through OUR Apex SuiteS
02
flexible cell line optimization with VectorSelect
03
Enhanced cell lines for other biologics through VectorSelect
Read the latest
[64x Bio Launches LV Apex Suite, Expanding Its CellMap-Driven VectorSelect Platform Into Lentiviral Vector Production 64x Bio
Experts in scalable bioengineering
64x is on a mission to unlock the potential of next generation therapies by reengineering how they’re made.